ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FAB Fusion Antibodies Plc

3.80
0.15 (4.11%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.15 4.11% 3.80 3.70 3.90 3.80 3.65 3.65 1,463,194 14:00:28
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0272 -1.40 3.62M
Fusion Antibodies Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 3.65p. Over the last year, Fusion Antibodies shares have traded in a share price range of 3.10p to 9.875p.

Fusion Antibodies currently has 95,365,564 shares in issue. The market capitalisation of Fusion Antibodies is £3.62 million. Fusion Antibodies has a price to earnings ratio (PE ratio) of -1.40.

Fusion Antibodies Share Discussion Threads

Showing 4076 to 4099 of 4100 messages
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older
DateSubjectAuthorDiscuss
24/5/2024
13:15
Fusion will be presenting at the Proactiveinvestor one2one meeting next week (Wednesday 29th May), it looks like a good line up, so I shall go along to that:
timbo003
23/5/2024
17:42
Fusion write-uphttps://spongeshare.com/2024/05/23/trade-idea-is-fusion-at-an-inflection-point-with-its-latest-offerings-including-its-ai-platform-and-contract-wins/
maverick247
23/5/2024
15:07
Only on Aim not fit for purpose
bobaxe1
23/5/2024
14:07
Only on not fit for purpose
bobaxe1
23/5/2024
11:51
I do see signs of potential.New contracts are coming in, even if they are small.However, if this share price is to jump it needs:At least one of the contracts to commercialise and generate revenues via royaltiesMore contracts, to avoid having to ask the market for more cash.At the moment, it is a very speculative share.
paulisi
23/5/2024
09:47
Good traders shaken out now let it go
bobaxe1
23/5/2024
08:41
Second push breaks and holds above 4.Shook a few out and propel it higher standard really
soultrading
23/5/2024
08:35
Long term I definitely think 40/50 achievable from this level. They’ve developed and commercialised new technology since 2022, they’re generating new clients in new markets and revenues are recovering. They traded at 194p in 2020! Not out of the question to get back to that level when news about the NCI partership breaks and generates significant revenues
gtc1508
23/5/2024
08:27
How many bags
bobaxe1
23/5/2024
08:20
Yes great news out today for FAB and IXI should both rally
citys2874
23/5/2024
07:56
Decent news
soultrading
23/5/2024
07:25
RNS out and very positive. Looks like the US based biotech is increasingly trusting Fusion to deliver
ksddw2
22/5/2024
12:48
Very little under 3.7 available before next move higher
soultrading
21/5/2024
09:06
Oops, that should have been on the Lung Life AI group. Very sorry, everyone. Thank you, Trout, for pointing out my mistake. I can't delete the post from my phone but will do as soon as I access my laptop.
gregb
21/5/2024
08:45
You must be on the wrong thread???
troutisout
21/5/2024
07:42
Deleted Post. Wrong thread, sorry.
gregb
20/5/2024
10:57
Fusion’s market capitalisation is £3.3m, suggesting an EV of £2.1m, based on year £1.2m end cash. We consider this to represent an interesting special situation geared to the success of Fusion’s recovery plan, where almost no value is currently being ascribed to its class leading antibody discovery technologies. This unusual situation has arisen as a result of the steep decline in revenue Fusion experienced in H2 FY23 that extended into FY24.

Given there is evidence of a turnaround in its fortunes and helped by an improved funding environment for biotech generally and its order book is now on an upward trajectory, our investment thesis is that investors will start to recognise the value inherent in Fusion’s class leading antibody discovery technology. To highlight this, we would draw attention to the valuation of Absci (Nasdaq: ABSI), an albeit much-larger US/Canadian-based firm that has an AI-led approach to antibody drug design. This company has a market capitalisation of $535m and cash of $72m, so has an EV of $463m.

gtc1508
16/5/2024
18:12
Investor presentation link
gtc1508
15/5/2024
23:28
Another £100k grant funded project there involved inToday 23:26
Another £100k grant funded project there involved in, awarded in April this year:

hxxps://gtr.ukri.org/projects?ref=10106193

The project's primary objective is to establish a local supply chain to produce Titan test kits. Causeway will use subcontractors to carry out critical elements of the kit assembly process. Fusion Antibodies, world experts in antibody production, will manufacture and purify an IgG1 monoclonal antibody, which will be used as the standard in the Titan test kits.

The project aims to generate real-time data by monitoring antibody production and purification processes at Fusion Antibodies. This data will be used to create application notes and technical documentation for Titan, providing valuable insights into its performance and applications.

Causeway Sensors anticipates that Titan will significantly impact biopharmaceutical manufacturing, introducing advanced process analytical testing (PAT) sensors for more efficient and data-informed manufacturing of biotherapeutics. The project reflects our commitment to local collaboration and expertise development in this field, contributing to increased activity in Northern Ireland's growing Life Sciences sector.

gtc1508
15/5/2024
16:36
Investor meet company presentation tomorrow 11am
bobaxe1
14/5/2024
22:28
Chart building!//https://x.com/darrenukdaytra1/status/1790328577944109057?s=46&t=KHNNXk1Nw1j5lyzHBSnKag
bobaxe1
13/5/2024
11:07
Slow starting so far. A number of people talked about buying in before presentation so hopefully when one buys the others will jump in to.
soultrading
12/5/2024
09:46
Could be a good week ahead.
soultrading
10/5/2024
09:37
Be nice to close above 3.5 that would get the technical traders in.
soultrading
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older

Your Recent History

Delayed Upgrade Clock